Sitemap
Main Menu
Corporate Menu
- About Us
- Directors & Management
- Company Information
- Reports
- Announcements
- Passing of Dr. Malcolm Simons
- ASX Quarterly Reports - 31 December 2011
- ASX share price query and response - 27 January 2012
- Genetic Technologies Appoints Dr. Mel Bridges as Chairman
- Genetic Technologies research coverage initiated by US Investment Bank, Ladenburg Thalmann
- Genetic Technologies Executes Settlement and License Agreement with AutoImmun Diagnostika GmbH
- US Annual Report on Form 20-F
- Results from 2011 Annual General Meeting
- 2011 Annual General Meeting materials
- ImmunAid Press Release
- Forfeiture of options - 24 October 2011
- Presentation at AusBiotech 2011
- Genetic Technologies' BREVAGen changing the way US physicians assess breast cancer risk
- 2011 Notice of Annual General Meeting and Proxy
- Appointment of Dr. Mervyn Cass
- Investor presentation at Rodman & Renshaw
- ASX Appendix 4E - 30 June 2011
- GTG maiden full year profit
- Settlement with Attomol GmbH
- Placement of shares and ASX Appendix 3B
- Cleansing notice
- Completion of Successful Capital Raising
- Response to Price and Volume Query
- Market Update
- Genetic Technologies Executes Settlement and License Agreement with Navigenics Inc.
- Launch of BREVAGen test in US
- SERL substantial shareholder notice - 6 June 2011
- US Investor Presentation - June 2011
- GTG GENE processes first BREVAGen sample
- Appendix 3B - 26 May 2011
- Filing Of Further Patent Infringement Suit
- Genetic Technologies secures CLIA certification
- Collaboration with Global Pharmaceutical Company
- GTG Settlement with ViennaLab
- GTG Conclusion of First Assertion 13Apr2011
- Granting of license to Orchid Cellmark
- Appendix 3Y for Huw Jones - 24 March 2011
- ASX Half Yearly Report 31 December 2010
- Genetic Technologies Forensics Testing extended by NSW Police
- Appendix 3B - 7 February 2011
- Maiden Half Year Profit
- Form 605 - James Edward Besser
- Settlement of dispute with Sunrise Medical
- Australian Investor January 2011 - Genetic Technologies to Launch Innovative Breast Cancer Test
- US investor presentation
- Sky News – ‘Summer Money’ interview with CEO Paul MacLeman, 7.30pm Thursday 6th January, 2011
- Granting of license to Qiagen
- Appendix 3Y for Huw Jones - 9 December 2010
- Settlement of dispute with Pioneer Hi-Bred
- 2010 Annual General Meeting materials
- Results from 2010 Annual General Meeting
- Granting of license to Laboratoires Reunis
- Settlement of dispute with Innogenetics NV
- ASX Quarterly Reports - 30 September 2010
- Presentation - October 2010
- 2010 Annual Report and Notice of Annual General Meeting
- Expiry of options - 12 October 2010
- Financial Report - 30 June 2010 with Audit Reports
- ASX Appendix 4E - 30 June 2010
- Monsanto license - August 2010
- ASX Quarterly Reports - 30 June 2010
- ASX Appendix 3B with covering letter
- Transfer to NASDAQ Capital Market
- Extension of Quest license
- Appointment of Lewis Stuart
- BREVAGen data presented at ASCO 2010
- Patent claims upheld in full by USPTO
- EraGen Biosciences License
- Gen-Probe License
- Acquisition of BREVAGen
- Private placement of shares and ASX Appendix 3B
- GTG Investor Update - March 2010
- NASDAQ press release - 16 March 2010 Marketplace Rule 5810(b)
- Expiry of options - 2 March 2010
- ASX Appendix 4D - 31 December 2009 with Financial Report
- Assertion of property rights
- BioBusiness TV - GTG
- Lodgement of Appendix 4C
- Genetic Technologies Limited Broadcast
- Exclusive Distribution Agreement with Response Genetics, Inc.
- BREVAGen Option Agreement
- Lodgement of Appendix 3Z
- Lodgement of Appendix 3X
- Appointment of Mr. Tom Bonvino as Company Director
- Results from 2009 Annual General Meeting
- Resignation of Mr. Fred Bart as Chairman and Company Director
- Materials for 2009 Annual General Meeting
- Lodgement of Appendix 4C
- Shareholder Update
- Exclusive Distribution Agreement with Rosetta Genomics Inc.
- 2009 Annual Report and Notice of Annual General Meeting
- Appointment of Dr. Mal Brandon as Company Director
- Lodgement of Appendix 4E
- Genetic Technologies US Patent Update
- Withdrawal of German Nullification Action
- ImmunAid Project Update: Encouraging pilot results presented at ASCO
- Appointment of new Chief Executive Officer
- Expiry of Options
- Forfeiture of Options
- GTG Grants License to TIB MOLBIOL
- Lodgement of Appendix 3Z
- Resignation of Director
- New Position re BRCA Testing
- Lodgement of Appendix 3X
- Appointment Of New Directors
- Results from 2008 Annual General Meeting
- Lodgement of Appendix 3Y
- Intention To Appoint A Director
- Further Clarification On BRCA Testing
- Withdrawal Of Consent To Act As A Director
- 2008 Annual Report and Notice of Annual General Meeting
- GTG launches dog breed identification test
- Response to Notice of Intention to Move a Resolution
- Request for trading halt
- Preliminary Final Report
- Sale of exploration interest
- Genetic Technologies Clarifies Misconceptions on BRCA testing
- GTG acquires Frozen Puppies
- Genetic Technologies to enforce rights to BRCA patents
- Granting and cancellation of options
- Lodgement of Appendix 3Y
- GTG management update
- Appointment of Dr. Leanne Rowe AM to Board of Directors
- GTG awarded forensics outsourcing agreement by NSW Police
- GTG Licenses GE Healthcare
- Licensing Program Update
- Expiry and cancellation of options
- Results of 2007 Annual General Meeting
- Annual General Meeting Presentation
- Expiry and cancellation of options
- Lodgement of Appendix 3B
- 2007 Annual Report and Notice of Annual General Meeting
- Media & Investor Information
- Biotech Daily - The Year in Review - CEO Of The Year Dr Paul MacLeman
- GTG Appoints Biotech Doyen Chairman
- Ladenburg Thalmann Initiates Research Coverage.
- 2011 Annual Report
- RBS Morgan Research Note
- Lodge Partners Research Report - August 2011
- RBS Morgan - Genetic Technologies ProActive Approach
- Lodge Partners Research Report – July 2011
- GTG Newsletter May 2011
- The Asahi Shimbun
- Biotech Daily
- GTG Newsletter October 2010
- Shareholder Information
- Corporate Governance
- Shareholder Meetings & Notice
- Licensing
- Research & IP
External Menu
Footer Menu
Announcements
Latest News
